Ablynx And Merck Serono Launch Their Fourth Nanobody R&D Alliance
This article was originally published in The Pink Sheet Daily
Belgian drug-discovery company Ablynx and Germany’s Merck Serono have expanded their ties by creating a research alliance that may lead to the development of at least four Nanobody agents to treat disease.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.